Treace Medical Concepts (TMCI) Stock Price, News & Analysis

Company Overview

Treace Medical Concepts, Inc. is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company’s flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.

The Lapiplasty System has received clearance from the U.S. Food and Drug Administration and is supported by clinical evidence demonstrating its effectiveness for patients with moderate to severe bunion deformities. Treace works closely with a network of foot and ankle surgeons, offering hands-on training programs and educational resources to facilitate proper adoption of its technology in hospital and ambulatory surgery center settings. In addition to bunion correction, the company continues to explore adjacent applications in foot and ankle reconstruction.

Founded in 2017 and headquartered in Ponte Vedra Beach, Florida, Treace Medical Concepts initially built its commercial presence in North America and is evaluating opportunities for international expansion. The company’s management team brings together experienced medical device executives, orthopedic surgeons, and industry veterans committed to advancing the standard of care in foot and ankle surgery. Treace continues to invest in research and development as it seeks to broaden its product portfolio and drive long-term growth in the orthopedic market.

Key Stats

• Today's Range: $4.66 to $4.93
• 50-Day Range: $3.97 to $4.88
• 52-Week Range: $1.17 to $7.63
• Volume: 275,355 shs
• Average Volume: 391,615 shs
• Market Capitalization: $317.40 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.17
• Consensus Rating: Reduce

Treace Medical Concepts Stock Analysis - MarketRank™

Treace Medical Concepts scored higher than 58% of companies evaluated by MarketBeat, and ranked 331st out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.8 / 5
• Analyst Rating: Reduce

Consensus Rating

Treace Medical Concepts has received a consensus rating of Reduce. The company's average rating score is 1.86, and is based on no strong buy ratings, 1 buy rating, 4 hold ratings, and 2 sell ratings.

Upside/Downside

The consensus price target for Treace Medical Concepts is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Treace Medical Concepts has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Treace Medical Concepts are expected to grow in the coming year, from ($0.83) to ($0.81) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Treace Medical Concepts is -5.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Treace Medical Concepts is -5.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Treace Medical Concepts has a P/B Ratio of 4.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.20% of the float of Treace Medical Concepts has been sold short.

Short Interest Ratio / Days to Cover

Treace Medical Concepts has a short interest ratio ("days to cover") of 2.97, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Treace Medical Concepts has recently decreased by 6.08%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Treace Medical Concepts does not currently pay a dividend.

Dividend Growth

Treace Medical Concepts does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

Treace Medical Concepts has a news sentiment score of 1.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Treace Medical Concepts this week, compared to 2 articles on an average week.

MarketBeat Follows

1 people have added Treace Medical Concepts to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 4.3 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $457,613.00 in company stock, which represents 0.1442% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Treace Medical Concepts insiders have bought more of their company's stock than they have sold. Specifically, they have bought $457,613.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

23.42% of the stock of Treace Medical Concepts is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

84.08% of the stock of Treace Medical Concepts is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/07/2026
• Today: 9/04/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:TMCI
• CIK: 1630627
• Web: www.treace.com
• Phone: 904-373-5940
• Fax: N/A
• Employees: 250
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Treace Medical Concepts: $5.17
• High Price Target: $7.00
• Low Price Target: $3.00
• Potential Upside/Downside: +5.9%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.86
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.93)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$59 million
• Net Margins: -28.99%
• Pretax Margin: -28.99%
• Return on Equity: -71.37%
• Return on Assets: -30.49%

Debt

• Debt-to-Equity Ratio: 0.83
• Current Ratio: 2.90
• Quick Ratio: 1.95

Sales & Book Value

• Annual Sales: $212.69 million
• Price / Sales: 1.49
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.04 per share
• Price / Book: 4.69

Miscellaneous

• Outstanding Shares: 65,040,000
• Free Float: 49,804,000
• Market Cap: $317.40 million
• Optionable: Optionable
• Beta: 1.40